Usage and dosage of therapeutic agents for endometriosis
An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.
1. A pharmaceutical composition for treating endometriosis or an endometriosis-associated pain in a patient, the pharmaceutical composition comprising a compound represented by 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof,
wherein the pharmaceutical composition is orally administrable, and
wherein the pharmaceutical composition comprises the compound in an amount of from 50 mg to 75 mg calculated as a free form, the amount being therapeutically effective for treating the endometriosis or the endometriosis-associated pain in the patient.
2. The pharmaceutical composition according to claim 1 ,
wherein the pharmaceutically acceptable salt is 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt.
3. The pharmaceutical composition according to claim 1 ,
wherein the pharmaceutical composition comprises 50 mg of the compound calculated as a free form.
4. The pharmaceutical composition according to claim 1 ,
wherein the pharmaceutical composition comprises 75 mg of the compound calculated as a free form.
5. A method for treating endometriosis or an endometriosis-associated pain, the method comprising:
administering orally once daily the pharmaceutical composition according to claim 1 to a patient.
6. A method for treating endometriosis, the method comprising:
administering a therapeutically effective amount of a pharmaceutical composition comprising a compound represented by 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof to a patient,
the compound being administered orally once a day at a daily dose of from 50 mg to 75 mg calculated as a free form.
7. The method according to claim 6 ,
wherein the pharmaceutically acceptable salt is 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt.
8. The method according to claim 6 ,
wherein the daily dose is 50 mg calculated as a free form.
9. The method according to claim 6 ,
wherein the daily dose is 75 mg calculated as a free form.
10. A method for treating endometriosis-associated pain, the method comprising:
administering a therapeutically effective amount of a pharmaceutical composition comprising a compound represented by 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof to a patient,
the compound being administered orally once a day at a daily dose of from 50 mg to 75 mg calculated as a free form.
11. The method according to claim 10 ,
wherein the pharmaceutically acceptable salt is 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt.
12. The method according to claim 10 ,
wherein the daily dose is 50 mg calculated as a free form.
13. The method according to claim 10 ,
wherein the daily dose is 75 mg calculated as a free form.